Conference abstract
Study theme · illustration
Read the results alongside the study design, safety findings and limitations.

Who was studied?

66 enrolled patients as of 31 October 2024.

What does the publication report?

In 66 patients, ORR was 22.7% (15/66), DCR 56.1% (37/66), median PFS 4.3 months, and median OS 10.3 months.

Safety findings

TRAEs occurred in 57/66 (86.4%) patients; 6/66 (9.1%) had grade ≥3 events.

How should we interpret it?

Conference abstract with limited methodological detail and no randomized comparator; linked to the same PRaG 2.0 study, not a separate trial.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: a prospective, multicenter clinical trial. · DOI: 10.1200/JCO.2025.43.16_suppl.2616

Related publications from the same research program

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.